EpiCept’s vision is to create and develop products that make a meaningful difference in people’s lives. As such, it is dedicated to successfully increasing the life span of cancer patients and continually improving the quality of life of pain sufferers.

Our mission is the relentless pursuit of satisfying unmet medical needs with pharmacologic agents that are based on sound scientific findings, demonstrated safety and efficacy, and unique and proven technologies. We are focused on advancing a pipeline of world-class products that treat malignant diseases and moderate-to-severe pain.

EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of cancer and pain. The Company's lead product is Ceplene(R), which has been granted full marketing authorization by the European Commission for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia in first remission. The Company has two oncology drug candidates currently in clinical development that were discovered using in-house technology and have been shown to act as vascular disruption agents in a variety of solid tumors.

In the area of pain, EpiCept’s product candidates are designed to topically deliver FDA-approved pain management therapeutics directly to the surface of the skin, which the Company believes will offer patients a safer, more beneficial form of pain relief than traditional systemic forms of analgesics. Because these product candidates utilize FDA-approved drug substances, EpiCept believes that there will be a more streamlined regulatory approval pathway for these product candidates, reducing development risk and costs and potentially accelerating the time to market. The Company's pain portfolio includes EpiCeptTM NP-1, a prescription topical analgesic cream in late-stage clinical development designed to provide effective long-term relief of pain associated with peripheral neuropathies.

EpiCept seeks to generate significant value for its shareholders by developing effective drug candidates, including new chemical entities and new uses for existing therapies, advancing them into late-stage clinical development and then seeking marketing approval either alone or in conjunction with strategic partners.